Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia

Neuropsychopharmacology

Volumn 35, Issue 2, 2010, Pages 581-590

  Kinon, Bruce J ^a   Chen, Lei ^a   Ascher Svanum, Haya ^a   Stauffer, Virginia L ^a   Kollack Walker, Sara ^a   Zhou, Wei ^a   Kapur, Shitij ^b   Kane, John M ^c  

^a ELI LILLY AND COMPANY   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Atypical antipsychotic; Early response; Prediction; Risperidone; Schizophrenia

Indexed keywords

OLANZAPINE; RISPERIDONE;

ADULT; AGITATION; AKATHISIA; ANXIETY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; LETHARGY; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROLACTIN; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TRIGLYCERIDES;

EID: 72449167382     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.164     Document Type: Article

References (38)

1. Agid O, Kapur S, Arenovich T, Zipursky RB (2003). Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60: 1228-1235.
2. Alvarez E, Ciudad A, Olivares JM, Bousoño M, Gómez JC (2006). A randomized, 1-year follow-up study of olanzapine and risper-idone in the treatment of negative symptoms in outpatients with schizophrenia. J Clin Psychopharmacol 26: 238-249.
3. Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A (2008). Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull 34: 1163-1171.
4. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
5. Canive JM, Miller GA, Irwin JG, Moses SN, Thoma RJ, Edgar JC et al (2006). Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design. Psychopharmacol Bull 39: 105-116.
6. Conley RR, Mahmoud R (2001). A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 158: 765-774.
7. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM (2003). Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 160: 2063-2065.
8. Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553-564.
9. Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J et al (2004). Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 65: 312-321.
10. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA (2006). Effectiveness of switching antipsychotic medications. Am J Psychiatry 163: 2090-2095.
11. Falkai P (2008). Limitations of current therapies: why do patients switch therapies? Eur Neuropsychopharmacol 18: S135-S139.
12. Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ (2008). Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia. Curr Med Res Opin 24: 1399-1405.
13. Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH (2009). A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 65: 510-517.
14. Ganguli R, Brar JS, Mahmoud R, Berry SA, Pandina GJ (2008). Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. BMC Med 6: 17.
15. Guy W (1976). ECDEU Assessment Manual for Psychopharmacol-ogy Revised (Publication ADM 76-338) US Departmnet of Health, Education, and Welfare: Rockville, MD. pp 218-222.
16. Hardy TA, Marquez E, Kryzhanovskaya L, Taylor CC, Cavazzoni P (2006). Cross-sectional comparison of fasting lipids in normo-glycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. J Clin Psychopharmacol 26: 405-408.
17. Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D et al (2007). Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 17: 235-244.
18. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
19. Kelly DL, Conley RR, Love RC, Morrison JA, McMahon RP (2008). Metabolic risk with second-generation antipsychotic treatment a double-blind randomized 8-week trial of risperidone and olanzapine. Ann Clin Psychiatry 20: 71-78.
20. Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA (2006). Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional anti-psychotics or risperidone to olanzapine. Psychoneuroendocri-nology 31: 577-588.
21. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL et al (2008). Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 102: 230-240.
22. Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A et al (1993). Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 29: 309-314.
23. Konarzewska B, Wolczynski S, Szulc A, Galinska B, Poplawska R, Waszkiewicz N (2009). Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinol-ogy 34: 129-139.
24. Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005a). Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 57: 1543-1549.
25. Leucht S, Busch R, Kissling W, Kane JM (2007). Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 68: 352-360.
26. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR (2005b). What does the PANSS mean? Schizophr Res 79: 231-238.
27. Leucht S, Shamsi SA, Busch R, Kissling W, Kane JM (2008). Predicting antipsychotic drug response. Replication and extension to six weeks in an international olanzapine study. Schizophr Res 101: 312-319.
28. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
29. Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM et al (2008). Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res 103: 104-109.
30. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
31. Overall JE, Gorham DR (1962). The brief psychiatric rating scale. Psychol Rep 10: 799-812.
32. Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S et al (2009). Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res 107: 22-29.
33. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11-19.
34. Simpson GM, O'Gorman CJ, Loebel A, Yang R (2008). Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia. CNS Spectr 13: 898-905.
35. Takahashi H, Kamata M, Yoshida K, Ishigooka J, Higuchi H (2006a). Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial. J Clin Psychiatry 67: 1577-1582. (Pubitemid 44787441)
36. Takahashi H, Yoshida K, Ishigooka J, Higuchi H (2006b). Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial. Prog Neuropsychopharmacol Biol Psychiatry 30: 1067-1072. (Pubitemid 44202366)
37. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley Jr C et al (1997). Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17: 407-418.
38. Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M et al (2006). Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional anti-psychotic therapy: a switch study. J Psychiatr Res 40: 669-676